TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in frequency of migraine attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in the number of hypoglycaemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain Scores at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores on Coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: latencies of nociceptive evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amplitudes of nociceptive evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharyngeal pressure differentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Video endoscopy of pharyngeal collapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Text reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Text reading accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of successes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - maximum observed concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-last - area under the concentration-time curve from zero to the time of the last measurable concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ - area under the concentration-time curve from zero to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain from procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Inhibitory Curve (AUIC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PCR results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Net protein synthesis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant post-ERCP bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Disabling stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Re-hospitalization for cardiovascular causes or bleeding
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Karlsson score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean change in clinical attachment level (CAL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cup migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Motor Assessment Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Concentration of Tramadol and Tramadol Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Family planning take up
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Purchase of pregnancy test kit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Brain Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number and type of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Neointimal healing score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Achievement of preparation adequacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Persistence and adherence to treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in markers of preclinical cardiovascular disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in global cardiovascular risk based on the ESH/ESC table of risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of metabolite peaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Posttraumatic Stress Disorder Checklist (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in eGFR From Baseline at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Vital signs (pulse rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vital signs (blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Discontinued the Study Due to an AE
Endpoint domain: Adverse events/effects
Primary endpoint: GIRmax After a Single Dose Administration of Subcutaneous MK-1092 or Glargine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) for AZD9977
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS IV) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants Meeting the Criteria for Responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events and Adverse Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: amount of bleeding during operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operation duration time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration-time curve (AUC(TAU))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of AT-501 vaccine measured by Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Immunogenicity of AT-501 vaccine measured by HI titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in scales for Autism spectrum disorders
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurophysiological reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Peak electrical activity of the diaphragm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of caregivers who made critical CSS use errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in total number of CSS use errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of Regional Acceleratory Phenomenon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Root Resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure (IOP) patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of participants achieving MBL volume < 80 mL and ≥ 50% reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changed walking pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of responders with stable or improved cognitive function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Plasma HIV-1 RNA <50 c/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the frequency of Treg in R group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of the frequency of Breg in R group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of the frequency of Treg in N group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of the frequency of Breg in N group
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of cases with healed anal fissure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Residual Refractive Cylinder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Inhibition Tasks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Isokinetic Strength measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Serum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time Zero to the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of M1 disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Faces pain scale - R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Discharge Time to Modified Aldrete Score ≥18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of mood disorders episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Variation of the Medical Outcome Study Short Form 36 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom Severity Index - First Randomization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom Severity Index - Second Randomization
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Half-life of detectable HSV-2 DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proximal tibia angle (PTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-dislocation of shoulder
Endpoint domain: Adverse events/effects
Primary endpoint: Comprehensive Complication Index
Endpoint domain: Adverse events/effects
Primary endpoint: Tinnitus severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinical evolution characterized by escalation or stabilization/improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline of the speed threshold at 1 week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anatomical and functional characteristics of the ruptured rotator cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Aortic Systolic Blood Pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic Diastolic Blood Pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic Mean Arterial Pressure (MAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Female Fetal Testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Lens Surface Wettability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Surface Deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Lens Fit Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnostic sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-month seizure freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: onset time 95% maximum depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical duration T1 25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full recovery 0.8-0.9 TOF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rates of other complications of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of procedure-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Time in Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of anemic patients to screened patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Radiographic whole defect depth change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of fear of hypoglycemia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Injection pain due to rocuronium
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with unsatisfactory outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical success of GORE® Septal Occluder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of at least 30% of the biggest diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Clinician Administered PTSD Scale (CAPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brief Assessment of Cognition in Affective Disorders (BAC-A)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Positive and Negative Symptoms Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by Visual Analogue Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Tumour Necrosis Factor-alpha (TNF-α) in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Level of Interleukin-6 (IL-6) in Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change in number of arrested caries surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: β-endorphins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSA-progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in neuroinflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiopulmonary Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 30 days mortality
Endpoint domain: Mortality/survival
Primary endpoint: Dilation free time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of cardiovascular endpoints
Endpoint domain: Mortality/survival
Primary endpoint: Reliability and validity of Thai version of ESAS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Preoperative treatment-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative surgical morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Length of hospital stay following pancreatic resection
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anti PT IgA levels in colostrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diaphragm function test modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm fatigue test modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm performance test modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diaphragm motion test modification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline values for clinical laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Individual evaluation of HCV RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: incidence of gingival clefts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetics of enzalutamide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP concentration (mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood-oxygen-level dependent (BOLD) responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Carriage prevalence of N.meningitidis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of infection-specific T-cell infusion and vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Hb Change Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Weekly Epoetin Dosage Per kg Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin A1C at 4 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Femoral artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of Brief Sleep Disturbance Scale (BSDS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Presence of positive amyloid retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in PF-10 score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Eosinophils Recovered Following Segmental Allergen Challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sum of Pain Intensity Difference (SPID) 1-3 Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kinome activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in advance care planning engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Trough forced expiratory volume (FEV1) response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: FEV1 area under curve 3 to 6 hours (AUC0-6h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Fugl-Meyer Assessment (lower)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FAC (Functional ambulatory scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to All-cause Death
Endpoint domain: Mortality/survival
Primary endpoint: IL-8 production by PMN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentrations and adequacy of antimicrobial activity of antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Flow-mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insulin-mediated Skeletal Muscle Glucose Utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Adverse Safety Events During Hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: two-year recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pain assessment using Visual Box Scale (VBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of 18F-NaF
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy profile of 18F-NaF compared to 99mTc-biphosphonate bone scintigraphy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frontal Behavioral Inventory, disinhibition subscale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Heart failure signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Sonographic Lean Body Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Alcohol-Exposed Pregnancy (AEP) risk at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes